Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT (NASDAQ:XENT)

Intersect ENT logoIntersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XENT
  • CUSIP: N/A
  • Web: www.intersectent.com
Capitalization:
  • Market Cap: $723.62 million
  • Outstanding Shares: 28,772,000
Average Prices:
  • 50 Day Moving Avg: $20.64
  • 200 Day Moving Avg: $15.05
  • 52 Week Range: $7.65 - $25.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -53.51
  • P/E Growth: -1.62
Sales & Book Value:
  • Annual Revenue: $82.49 million
  • Price / Sales: 8.77
  • Book Value: $3.83 per share
  • Price / Book: 6.57
Profitability:
  • EBIDTA: ($23,420,000.00)
  • Net Margins: -35.69%
  • Return on Equity: -21.25%
  • Return on Assets: -19.16%
Debt:
  • Current Ratio: 9.37%
  • Quick Ratio: 8.84%
Misc:
  • Average Volume: 332,476 shs.
  • Beta: 0.82
  • Short Ratio: 3.27
 

Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT Inc (NASDAQ:XENT) announced its earnings results on Tuesday, May, 2nd. The company reported ($0.23) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.02. The business earned $20.47 million during the quarter, compared to analysts' expectations of $19.39 million. Intersect ENT had a negative net margin of 35.69% and a negative return on equity of 21.25%. View Intersect ENT's Earnings History.

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?

10 brokers have issued 12-month price targets for Intersect ENT's stock. Their predictions range from $14.00 to $26.00. On average, they anticipate Intersect ENT's stock price to reach $18.78 in the next twelve months. View Analyst Ratings for Intersect ENT.

What are analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:

  • 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (5/3/2017)
  • 2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)

Are investors shorting Intersect ENT?

Intersect ENT saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 462,782 shares, a decrease of 36.1% from the April 28th total of 723,909 shares. Based on an average trading volume of 650,336 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.8% of the company's shares are short sold.

Who are some of Intersect ENT's key competitors?

Who owns Intersect ENT stock?

Intersect ENT's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (10.17%), Jennison Associates LLC (8.07%), Vanguard Group Inc. (3.72%), Neuberger Berman Group LLC (3.08%), Paulson & CO. Inc. (2.22%) and Morgan Stanley (2.10%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Frederic H Moll, James Stambaugh, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Who sold Intersect ENT stock? Who is selling Intersect ENT stock?

Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Jennison Associates LLC, Kornitzer Capital Management Inc. KS, Citadel Advisors LLC, Bellevue Group AG, Wells Fargo & Company MN, JPMorgan Chase & Co. and Menta Capital LLC. Company insiders that have sold Intersect ENT stock in the last year include Amy Wolbeck, James Stambaugh, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.

Who bought Intersect ENT stock? Who is buying Intersect ENT stock?

Intersect ENT's stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., FMR LLC, Marshall Wace LLP, Neuberger Berman Group LLC, Formula Growth Ltd., Vanguard Group Inc., MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. View Insider Buying and Selling for Intersect ENT.

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intersect ENT stock cost?

One share of Intersect ENT stock can currently be purchased for approximately $25.15.

Analyst Ratings

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $18.78 (25.34% downside)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
5/4/2017Northland SecuritiesBoost Price TargetOutperform$17.00 -> $22.00HighView Rating Details
5/3/2017Canaccord GenuityReiterated RatingBuyHighView Rating Details
5/3/2017WedbushBoost Price TargetOutperform -> Outperform$25.00 -> $26.00HighView Rating Details
3/6/2017Deutsche Bank AGUpgradeHold -> Buy$15.00 -> $19.00N/AView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$20.00N/AView Rating Details
11/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $14.00N/AView Rating Details
11/2/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$25.00 -> $16.00N/AView Rating Details
8/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$21.00N/AView Rating Details
8/4/2016BTIG ResearchReiterated RatingHold$14.00N/AView Rating Details
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00N/AView Rating Details
12/18/2015Bank of America CorpInitiated CoverageBuy$26.00N/AView Rating Details
10/2/2015Sterne Agee CRTReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Intersect ENT (NASDAQ:XENT)
Earnings by Quarter for Intersect ENT (NASDAQ:XENT)
Earnings History by Quarter for Intersect ENT (NASDAQ:XENT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017($0.25)($0.23)$19.39 million$20.47 millionViewListenView Earnings Details
2/28/2017Q416($0.20)($0.17)$23.47 million$24.20 millionViewListenView Earnings Details
11/2/2016Q316($0.27)($0.22)$17.80 million$18.50 millionViewN/AView Earnings Details
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intersect ENT (NASDAQ:XENT)
2017 EPS Consensus Estimate: ($0.73)
2018 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.22)($0.24)
Q2 20173($0.19)($0.19)($0.19)
Q3 20173($0.24)($0.14)($0.20)
Q4 20173($0.14)($0.06)($0.11)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ:XENT)
Insider Ownership Percentage: 13.90%
Institutional Ownership Percentage: 77.81%
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Richard E KaufmanCOOSell20,000$22.87$457,400.00View SEC Filing  
5/15/2017Lisa D EarnhardtInsiderSell20,000$22.98$459,600.00View SEC Filing  
4/20/2017Richard E KaufmanCOOSell1,250$17.25$21,562.50View SEC Filing  
4/17/2017Lisa D EarnhardtInsiderSell20,000$16.06$321,200.00View SEC Filing  
3/15/2017Lisa D EarnhardtInsiderSell20,000$15.02$300,400.00View SEC Filing  
10/20/2016Richard E KaufmanCOOSell3,603$16.58$59,737.74View SEC Filing  
10/17/2016Lisa D EarnhardtInsiderSell400$18.00$7,200.00View SEC Filing  
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.12View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.00View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.00View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.00View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.00View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.00View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.00View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Intersect ENT (NASDAQ:XENT)
Latest Headlines for Intersect ENT (NASDAQ:XENT)
Source:
DateHeadline
americanbankingnews.com logoFY2017 EPS Estimates for Intersect ENT Inc Decreased by Leerink Swann (XENT)
www.americanbankingnews.com - May 25 at 7:42 AM
americanbankingnews.com logoInsider Selling: Intersect ENT Inc (XENT) COO Sells 20,000 Shares of Stock
www.americanbankingnews.com - May 23 at 7:46 PM
streetinsider.com logoIntersect ENT (XENT) Announces 01/07/18 PDUFA Date for SINUVA ... - StreetInsider.com
www.streetinsider.com - May 22 at 8:05 AM
finance.yahoo.com logoIntersect ENT Announces PDUFA Date for Office-Based SINUVA™ Steroid Releasing Sinus Implant
finance.yahoo.com - May 22 at 8:05 AM
americanbankingnews.com logoIntersect ENT Inc (XENT) Insider Sells $459,600.00 in Stock
www.americanbankingnews.com - May 16 at 7:32 PM
americanbankingnews.com logoIntersect ENT's (XENT) "Outperform" Rating Reiterated at William Blair
www.americanbankingnews.com - May 13 at 12:32 AM
americanbankingnews.com logoResearch Analysts Offer Predictions for Intersect ENT Inc's Q2 2017 Earnings (XENT)
www.americanbankingnews.com - May 12 at 7:50 AM
americanbankingnews.com logoIntersect ENT Inc (XENT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 8 at 11:28 AM
americanbankingnews.com logoIntersect ENT Inc (XENT) Expected to Announce Quarterly Sales of $22.7 Million
www.americanbankingnews.com - May 5 at 1:38 PM
americanbankingnews.com logoIntersect ENT Inc Expected to Post Q3 2017 Earnings of ($0.24) Per Share (XENT)
www.americanbankingnews.com - May 5 at 10:42 AM
americanbankingnews.com logoLeerink Swann Comments on Intersect ENT Inc's Q2 2017 Earnings (XENT)
www.americanbankingnews.com - May 5 at 7:37 AM
americanbankingnews.com logoIntersect ENT Inc Forecasted to Earn FY2019 Earnings of ($0.02) Per Share (XENT)
www.americanbankingnews.com - May 4 at 7:31 PM
americanbankingnews.com logoNorthland Securities Reiterates Outperform Rating for Intersect ENT Inc (XENT)
www.americanbankingnews.com - May 4 at 7:18 AM
americanbankingnews.com logoIntersect ENT's (XENT) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - May 4 at 12:06 AM
americanbankingnews.com logoIntersect ENT Inc (XENT) Given "Buy" Rating at Canaccord Genuity
www.americanbankingnews.com - May 4 at 12:00 AM
nasdaq.com logoNoteworthy Wednesday Option Activity: XENT, TGT, QRVO
www.nasdaq.com - May 3 at 7:03 PM
americanbankingnews.com logoZacks: Brokerages Expect Intersect ENT Inc (XENT) to Announce -$0.21 EPS
www.americanbankingnews.com - May 3 at 6:00 PM
americanbankingnews.com logoIntersect ENT Inc (XENT) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 3 at 4:58 PM
americanbankingnews.com logoIntersect ENT (XENT) Receiving Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - May 3 at 4:26 PM
finance.yahoo.com logoEdited Transcript of XENT earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 9:37 AM
americanbankingnews.com logoIntersect ENT Inc (XENT) Given New $26.00 Price Target at Wedbush
www.americanbankingnews.com - May 3 at 9:06 AM
finance.yahoo.com logoInvestor Network: Intersect ENT Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 6:50 PM
finance.yahoo.com logoIntersect ENT Reports First Quarter 2017 Results
finance.yahoo.com - May 2 at 6:50 PM
marketbeat.com logoIntersect ENT reports 1Q loss
marketbeat.com - May 2 at 6:38 PM
americanbankingnews.com logoIntersect ENT (XENT) Earning Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 30 at 8:25 AM
finance.yahoo.com logoIntersect ENT to Present at Bank of America Merrill Lynch 2017 ... - Yahoo Finance
finance.yahoo.com - April 28 at 2:30 AM
finance.yahoo.com logoIntersect ENT to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
finance.yahoo.com - April 28 at 2:30 AM
americanbankingnews.com logoIntersect ENT (XENT) Earns Media Impact Score of -0.11
www.americanbankingnews.com - April 27 at 8:34 AM
americanbankingnews.com logoIntersect ENT (XENT) Receiving Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 23 at 11:49 AM
americanbankingnews.com logoIntersect ENT Inc (XENT) Short Interest Up 11.0% in March
www.americanbankingnews.com - April 22 at 5:16 PM
americanbankingnews.com logoRichard E. Kaufman Sells 1,250 Shares of Intersect ENT Inc (XENT) Stock
www.americanbankingnews.com - April 21 at 9:32 PM
americanbankingnews.com logoIntersect ENT Inc (XENT) Insider Sells $321,200.00 in Stock
www.americanbankingnews.com - April 18 at 7:55 PM
americanbankingnews.com logoIntersect ENT (XENT) Receives Daily News Sentiment Rating of 0.28
www.americanbankingnews.com - April 18 at 12:42 PM
americanbankingnews.com logoIntersect ENT Inc (XENT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 15 at 9:50 AM
businesswire.com logoIntersect ENT to Report First Quarter 2017 Financial Results ... - Business Wire (press release)
www.businesswire.com - April 15 at 8:04 AM
finance.yahoo.com logoIntersect ENT to Report First Quarter 2017 Financial Results
finance.yahoo.com - April 15 at 8:04 AM
americanbankingnews.com logoIntersect ENT (XENT) Receiving Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - April 15 at 7:50 AM
americanbankingnews.com logo Brokerages Anticipate Intersect ENT Inc (XENT) Will Announce Quarterly Sales of $19.39 Million
www.americanbankingnews.com - April 14 at 1:38 PM
americanbankingnews.com logo Analysts Anticipate Intersect ENT Inc (XENT) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - April 12 at 2:27 PM
americanbankingnews.com logoIntersect ENT Inc (XENT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 11 at 9:42 AM
finance.yahoo.com logoETFs with exposure to Intersect ENT, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 6:35 PM
streetinsider.com logoIntersect ENT (XENT) Submits NDA to FDA for Office-Based RESOLVE Steroid Releasing Implant for Recurrent ... - StreetInsider.com
www.streetinsider.com - March 10 at 6:10 AM
streetinsider.com logoIntersect ENT (XENT) Submits NDA to FDA for Office-Based RESOLVE Steroid Releasing Implant for Recurrent Chronic Sinus Disease
www.streetinsider.com - March 9 at 5:49 AM
us.rd.yahoo.com logoIntersect ENT Submits New Drug Application to FDA for Office-Based RESOLVE Steroid Releasing Implant for Recurrent Chronic Sinus Disease
us.rd.yahoo.com - March 9 at 5:49 AM
benzinga.com logoIntersect's Pipeline Deserves More Credit; Deutsche Upgrades To Buy
www.benzinga.com - March 6 at 8:04 PM
finance.yahoo.com logoINTERSECT ENT, INC. Financials
finance.yahoo.com - March 4 at 8:46 PM
finance.yahoo.com logoEdited Transcript of XENT earnings conference call or presentation 28-Feb-17 9:30pm GMT
finance.yahoo.com - March 1 at 8:08 AM
us.rd.yahoo.com logoIntersect ENT Reports Fourth Quarter and Full Year 2016 Results
us.rd.yahoo.com - February 28 at 8:40 PM
biz.yahoo.com logoINTERSECT ENT, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - February 28 at 8:40 PM
biz.yahoo.com logoINTERSECT ENT, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
biz.yahoo.com - February 28 at 8:40 PM

Social

Chart

Intersect ENT (XENT) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff